Cahill represented the initial purchasers in connection with a Rule 144A offering of $1 billion aggregate principal amount of 6.750% senior notes due 2033 by DaVita Inc.
DaVita Inc. intends to use the net proceeds from the offering (i) to repay outstanding revolving credit facility borrowings, (ii) to pay any costs, fees and expenses in connection with the foregoing, and (iii) if any proceeds remain, for general corporate purposes, including, without limitation, for repurchases of capital stock, working capital and capital expenditures.
DaVita Inc. is a leading healthcare provider, specializing in dialysis and related healthcare management for patients with chronic kidney disease.